BackgroundThe aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors.MethodsThis multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant.ResultsFour thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided.ConclusionsThe HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

MPV and PDW are independent variables determining the severity of liver fibrosis, and the regression model that is established using these parameters along with other markers, may give more information about the severity of liver fibrosis.

A AB BS ST TR RA AC CT T O Ob bj je ec ct ti iv ve e: : The aim of this study was to investigate the independent variables for the degree of liver fibrosis in patients with chronic hepatitis C virus (HCV) infection. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : In this cross-sectional retrospective study, the patients were divided in two groups as Group A (patients with fibrosis score 0-2) and Group B (patients with fibrosis score 3-4) and they were compared in terms of age, gender, body mass index, alcohol consumption, presence of diabetes, serum HCV RNA, alanine aminotransferase, gamma-glutamyl transferase, and aspartate aminotransferase, total bilirubin, albumin, globulin and alkaline phosphatase levels, prothrombin time, blood thrombocyte count, splenomegaly in ultrasonographic examination, HCV genotype and liver steatosis. R Re es su ul lt ts s: : Of 201 patients, 93 (46.3%) were males; the median age was 51 (range: 18-77) years. It was found that serum gamma-glutamyl transferase and aspartate aminotransferase levels, age, prothrombin time and the presence of splenomegaly were independent variables predictive of advanced liver fibrosis. Odds ratio and p values were 1.984 and 0.013 for gamma-glutamyl transferase, 1.633 and 0.018 for aspartate aminotransferase, 1.861 and 0.003 for age, 5.598 and 0.008 for splenomegaly and 0.541 and 0.007 for prothrombin time, respectively. C Co on nc cl lu us si io on n: : The results of this study suggested that advanced age, elevated serum gamma-glutamyl transferase and, aspartate aminotransferase levels, prolonged prothrombin time and the presence of splenomegaly are independent variables determining severe liver fibrosis. K Ke ey y W Wo or rd ds s: : Liver cirrhosis; hepacivirus Ö ÖZ ZE ET T A Am ma aç ç: : Bu çalışmanın amacı kronik hepatit C virüsü (HCV) enfeksiyonlu olgularda karaciğer fibrozunun derecesini belirleyen bağımsız değişkenleri araştırmaktı. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Bu geriye dönük kesitsel çalışmada hastalar Grup A (fibroz skoru 0-2 olanlar) ve Grup B (fibroz skoru 3-4 olanlar) olarak iki gruba ayrıldı ve gruplar yaş, cinsiyet, beden kitle indeksi, alkol kullanımı, diyabet varlığı, serum HCV RNA, alanin aminotransferaz, gama-glutamil transferaz, aspartat aminotransferaz, total bilirubin, albumin, globulin ve alkalen fosfataz seviyeleri, protrombin zamanı, kan trombosit sayısı, ultrasonografide splenomegali varlığı, HCV genotip ve karaciğer yağlanması açısın-dan karşılaştırıldı. B Bu ul lg gu ul la ar r: : İkiyüz bir hastadan 93 (%46,3)'ü erkekti ve ortanca yaş 51 (alt ve üst sınırlar: 18-77 yıl) idi. Serum gama-glutamil transferaz ve aspartat aminotransferaz düzeyleri, yaş, protrombin zamanı ve splenomegalinin ileri karaciğer fibrozunu belirleyen bağımsız değişkenler olduğu bulundu. Odds oranı ve p değerleri gamaglutamil transferaz için 1,984 ve 0,013; aspartat aminotransferaz için 1,633 ve 0,018; yaş için 1,861 ve 0,003; splenomegali için 5,598 ve 0,008 ve protrombin zamanı için 0,541 ve 0,007 idi. S So on nu uç ...

HIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts.

As tumors in axillary lymph nodes are found in patients with an ovarian carcinoma, the treatment is also so important too. Metastasis to the breast be differentiated accurately from primary breast cancer, because prognosis and treatment differ significantly. Accurate diagnosis of these metastases may allow more appropriate therapy, such as chemotherapy, and prevent the patient from an unnecessary major breast surgery.

Ge liş ta ri hi/Re cei ved: 15.11.2012 Ka bul ta ri hi/Ac cep ted: 14.12.2012 © Viral Hepatit Dergisi, Ga le nos Ya y› ne vi ta ra f›n dan ba s›l m›fl t›r. / Viral Hepatitis Journal, pub lis hed by Ga le nos Pub lis hing. ABS TRACTObjective: Viral hepatitis and HIV infection are important health problems. The aim of this study was to investigate seropositivity of HBsAg, Anti-HBs, Anti-HCV and Anti-HIV in the patients who were admitted to Artvin State Hospital between October 2009 and October 2012. Materials and Methods: Blood samples from the patients are analysed in Abbot Architect İ 1000 (Abbott Laboratories, İllinois,USA) using chemiluminescence method. Results: Serologically 21865 patients are tested for HBsAg, 15284 patients are tested for Anti-HBs, 21330 patients are tested for Anti-HCV and 17935 patients are tested for Anti-HIV. In our study 3.96%, 35.06%, 0.85% and 0.05% of the patients are tested are found to be seropositive for HBsAg, Anti-HBs, Anti-HCV and Anti-HIV respectively. Conclusion:The results detected for seropositivity in Artvin are similar to those found in other regions of Turkey.

No abstract

OBJECTIVE:Colistin is a cationic polypeptide antibiotic with a cyclic structure that belongs to the polymyxin group. It was banned from clinical use because of its significant renal side effects, such as nephrotoxicity. However, the administration of colistin has recently been initiated again in the treatment of multi-drug resistant pathogens, such as Acinetobacter baumannii and Pseudomonas aeruginosa. Nephrotoxicity and neurotoxicity are the main problems encountered in the clinical use of polymyxins. The aim of this study was to determine the frequency and risk factors of colistin-related nephrotoxicity in the adult intensive care unit (ICU).METHODS:In this study, a retrospective review of patients who were followed up between January 1 and December 31, 2016 and who received colistin treatment in the adult ICU was performed. Retrospective computer records of age, sex, site of infection and microorganism breeding, daily creatinine values, and additional diseases were recorded and examined. Nephrotoxicity was assessed using the Risk, Injury, Failure, Loss, and End-stage kidney disease criteria.RESULTS:A total of 48 patients were included in the study. Of these, 50% were male. The mean age of the patients with nephrotoxicity was 59.73±22.38 years, and the mean age of those without nephrotoxicity was 58.00±22.39 years. A. baumanni was observed to be the causative microorganism in all patients, and the most frequent infection was pneumonia. Nephrotoxicity was investigated in 54.2% (n=26) of the patients. In this study, when risk factors for nephrotoxicity were evaluated, it was found that the presence of nephrotoxicity was greater in cases with chronic obstructive pulmonary disease, malignancy, or abdominal surgery in patients older than 65 years. In addition, mortality was greater in those who developed nephrotoxicity, although it was not statistically significant.CONCLUSION:In this study, the rate of nephrotoxicity was 54.2% in patients who received colistin in the ICU. Therefore, patients in the adult ICU receiving colistin therapy should be carefully monitored for the development of nephrotoxicity as a side effect.